DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Information source: Oncotherapeutics
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Myeloma

Intervention: Pomalidomide (Drug); Pegylated Liposomal Doxorubicin (PLD) (Drug); Dexamethasone (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Oncotherapeutics

Official(s) and/or principal investigator(s):
James R Berenson, MD, Principal Investigator, Affiliation: Oncotherapeutics

Overall contact:
Tevea KEM, Phone: 310-623-1207, Ext: 137, Email: tkem@oncotherapeutics.com


The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of a combination of three different drugs, pomalidomide, pegylated liposomal doxorubicin, and dexamethasone when used to treat relapsed (the disease came back) or refractory (the disease did not respond to past treatment) multiple myeloma. Different dosages (amount of study drug) of pomalidomide are first being tested to determine if there are any side effects or risks associated with combining this study drug with the other two listed. Once the optimal dose is decided on, the study will change its focus to determining the effectiveness of the study drug in this combination.

Clinical Details

Official title: A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

MTD of Pomalidomide

Overall Response Rate

Secondary outcome:

Number of Patients with Adverse Events

Time to Progression

Progression-free Survival

Time to First Response

Duration of Response

Overall Survival

Detailed description: This is a phase 1/2, multicenter, open label and nonrandomized study to evaluate the efficacy and safety of pomalidomide at daily dosages of 2, 3 or 4 mg in combination with intravenous (IV) dexamethasone at 40 mg/dose and Pegylated Liposomal Doxorubicin (PLD) at 5 mg/m2/dose for subjects with relapsed/refractory multiple myeloma (MM). The study consists of a screening period, followed by up to eight 28 day open label treatment cycles, a final assessment to occur 28 days after the end of the last treatment, and a follow-up period. Subjects eligible for this study will receive treatment with study drug for a maximum of eight 28 day treatment cycles. Subjects are to be treated to a maximum response plus 2 additional cycles (no more than 8 cycles will be allowed) or complete 8 cycles of therapy without disease progression. Pomalidomide, dexamethasone and PLD will be administered on the appropriate cycle days as shown below.

Cohort 1 Pomalidomide* - 2 mg, Dexamethasone** - 40 mg, PLD** - 5 mg/m2

Cohort 2 Pomalidomide* - 3 mg, Dexamethasone** - 40 mg, PLD** - 5 mg/m2

Cohort 3 Pomalidomide* - 4 mg, Dexamethasone** - 40 mg, PLD** - 5 mg/m2

* PO Days 1-21 ** IV Days 1, 4, 8 and 11 In all cohorts, if an unacceptable dose limiting toxicities (DLT) is not seen in any of the 3 subjects during the first cycle of any dose level, dose escalation will continue. All subjects in a cohort must complete a minimum of 28 days or a full cycle, whichever is longer, without a DLT before enrollment to the next cohort can begin. If a DLT is identified in 1 subject at any dose level during the first treatment cycle, an additional 3 subjects will be recruited to this dose level. A maximum of 6 subjects may be enrolled in each cohort. If an unacceptable DLT is observed in 2 subjects at any dose level, no further subjects will be recruited to this dose level. The maximum tolerated dose (MTD) will be declared as the highest dose level at which fewer than 33% of subjects experienced an unacceptable DLT. If pomalidomide at 4 mg is reached and fewer than 33% of subjects experience an unacceptable DLT, 4 mg will be accepted as the putative MTD. Once the MTD is established, further enrollment will continue to expand that dose cohort until the total sample size of 40 subjects is reached for the entire study. During the phase 2 portion of this study, subjects enrolled will have relapsed/refractory MM resistant to lenalidomide as demonstrated by progressive disease while on lenalidomide or that has relapsed within 8 weeks of the last dose of lenalidomide.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Diagnosis of MM based on standard criteria (Durie 1986)

- Currently has MM with measurable disease, defined as:

- a monoclonal immunoglobulin spike on serum electrophoresis of at least 0. 5 g/dL


- urine monoclonal protein levels of at least 200 mg/24 hours

- for patients without measurable serum and urine M-protein levels, an abnormal

free light chain ratio (normal value: 0. 26 - 1. 65)

- Currently has progressive MM that has relapsed or is refractory, defined as:

- For the phase 1: Relapsed following stabilization or a response to at least one

anti-myeloma regimen or refractory defined as progressed while receiving an anti-myeloma treatment

- For the phase 2: Refractory to lenalidomide as demonstrated by progressive

disease while on lenalidomide or that relapsed within 8 weeks of the last dose of lenalidomide either as a single agent or in combination.

- Prior treatment with four days or less of a total of 400 mg of prednisone (or an

equivalent potency of another steroid) for MM will not be considered a regimen

- Able to adhere to the study visit schedule and other protocol requirements

- ECOG performance status of 2 or greater at study entry

- Life-expectancy of greater than 3 months

- Lab tests within study ranges at study entry:

- Absolute neutrophil count > 1. 5 x 109/L

- Platelet count > 75 x 109/L

- Hemoglobin > 8 g/dL

- Calculated or measured creatinine clearance > 30 mL/minute

- Total bilirubin < 1. 5 x upper limit of normal (ULN)

- AST (SGOT) and ALT (SGPT) < 2 x ULN

- Serum potassium within the normal range

- Females of childbearing potential must have a negative serum or urine pregnancy test.

- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (subjects

intolerant to ASA may use warfarin or low molecular weight heparin) Exclusion Criteria:

- POEMS syndrome

- Plasma cell leukemia

- Primary amyloidosis

- Non-hematologic malignancy within the past 5 years with the exception of a)

adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas

- Impaired cardiac function or clinically significant cardiac diseases

- Severe hypercalcemia

- Any serious medical condition, laboratory abnormality, or psychiatric illness that

would prevent the subject from signing the ICF

- Any condition, including the presence of laboratory abnormalities, which places the

subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study

- Undergone major surgery within 28 days prior enrollment or has not recovered from

side effects of such therapy (Kyphoplasty is not considered to be a major surgery; however, the investigator is to discuss enrollment of a subject with a recent history of kyphoplasty with the medical monitor)

- Pregnant or breast feeding females. (Lactating females must agree not to breast feed

while taking lenalidomide)

- Received the following prior therapy:

- Pomalidomide

- Chemotherapy within 3 weeks of study drugs (6 wks for nitrosoureas)

- Corticosteroids (>10 mg/day prednisone or equivalent) within 3 weeks of study


- Immunotherapy or antibody therapy as well as thalidomide, lenalidomide, arsenic

trioxide or bortezomib within 21 days before study drugs

- Extensive radiation therapy within 28 days before study drugs. Receipt of

localized radiation therapy does not preclude enrollment.

- Use of any other experimental drug or therapy within 28 days of study drugs

- Known hypersensitivity to compounds of similar chemical or biological composition to

thalidomide, lenalidomide or doxorubicin.

- The development of erythema nodosum if characterized by a desquamating rash while

taking thalidomide or similar drugs

- Concurrent use of other anti-cancer agents or treatments

- Known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline

testing for HIV and hepatitis B or C is not required

Locations and Contacts

Tevea KEM, Phone: 310-623-1207, Ext: 137, Email: tkem@oncotherapeutics.com

Roy and Patricia Disney Family Cancer Center, Burbank, California 91505, United States; Recruiting
Donna Fernando, Phone: 818-748-4723, Email: donna.fernando@providence.org
Nikko Grub, Phone: 818-748-4723, Email: nikko.grub@providence.org
Martina Zalom, MD, Principal Investigator

California Cancer Associates for Research and Excellence, Encinitas, California 92024, United States; Recruiting
Beth Kimball, RN, Phone: 760-452-3909, Email: bkimball@pacificoncology.com
Jacqui Noble, Phone: 760-452-3909, Email: jnoble@pacificoncology.com
Alberto Bessudo, MD, Principal Investigator

Hematology Oncology Medical Group, Fresno, California 93720, United States; Suspended

Pacific Cancer Care, Salinas, California 93901, United States; Recruiting
Monica Castillo, RN, Phone: 831-755-1701, Ext: 124, Email: mocastillo@pacificcancercare.com
Anne Haghighat, RN, Phone: 831-755-1701, Ext: 167, Email: ahaghighat@pacificcancercare.com
Laura Stampleman, MD, Principal Investigator

Cancer Center of Santa Barbara, Santa Barbara, California 93105, United States; Recruiting
Heidi Heitkamp, Phone: 805-898-2117, Email: hheitkamp@ccsb.org
Megan Wingo, Phone: 805-898-2779, Email: mwingo@ccsb.org
Thomas Woliver, MD, Principal Investigator

Mission Hope Cancer Center, Santa Maria, California 93454, United States; Recruiting
Carol Herrin, RN, Phone: 805-346-3463, Email: carol.herrin@dignityhealth.org
Kathleen Kennedy, MD, Principal Investigator

James R Berenson, MD, Inc., West Hollywood, California 90069, United States; Recruiting
James Berenson, MD, Phone: 310-623-1222, Email: jberenson@imbcr.org
Regina Swift, RN, BSN, Phone: 310-623-1222, Email: rswift@berensononcology.com
Youram Nassir, MD, Sub-Investigator
Shahrooz Eshaghian, MD, Sub-Investigator
James Berenson, MD, Principal Investigator

Illinois Cancer Specialists, Niles, Illinois 60714, United States; Recruiting
Pian Moy, RN, Phone: 847-827-9060, Email: pian.moy@usoncology.com
Lisbeth Lynn, Phone: 847-827-9060, Email: lisbeth.lynn@usoncology.com
Leonard Klein, MD, Principal Investigator

Additional Information

Starting date: February 2012
Last updated: April 13, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017